Our Shareholders

The combined research strengths of Monash University and the University of Melbourne are world class, placing them in the top 5 globally in pharmacology, metabolism, and immunology, and in the top 10 in paediatrics, neurosciences and cardiology – thereby covering some of the most debilitating, costly diseases in the modern world.

The Universities collectively invest approximately AUD1B per annum in medical research funding and in 2016 attracted nearly half of the Australian national grant funding pool. Both Universities are members of the ‘Group of Eight’, an alliance of leading Australian universities recognised for their excellence in teaching as well as research. Between them, the Universities employ approximately 4,000 FTE staff in the biomedical sciences and provide major research infrastructure, healthcare and clinical research capabilities.

As individual institutions, Monash University and the University of Melbourne have differing, yet potentially highly complementary areas of expertise required for the early drug development process. This provides a compelling opportunity for BioCurate to be the catalyst to identify and leverage this combined expertise and build a strong pipeline of new drug targets with the potential to make a significant impact both medically and commercially.

 

As a modern, global, research-intensive university, Monash University creates positive change for present and future generations.

The University’s purpose is to meet the challenges of the age – climate change, geopolitical security and thriving communities – through excellent research and education for the benefit of national and international communities. Its impact is fuelled by a commitment to innovation and enterprise through advancing new ideas and facilitating the adoption and commercialisation of new intellectual property, in collaboration with other universities, governments, industry and not-for-profit organisations.

Home to the groundbreaking Victorian Heart Hospital and Moderna’s first mRNA production facility in the Southern Hemisphere, the University is a vital element of the Monash Health Network and the driving force behind the Monash Technology Precinct. It channels $626.5 million of its $1.3 billion annual research investment into health.

As a leading international medical research university with the largest medical faculty in Australia and integration with leading Australian teaching hospitals, Monash consistently ranks in the top-50 universities worldwide for clinical, pre-clinical and health sciences. Monash is ranked within the top two in the world for Pharmacy and Pharmacology (QS World University Rankings by Subject 2023).

Monash has four Australian campuses on the lands of the Kulin Nations. It also has campuses in Malaysia and Indonesia (the first foreign universities ever established in both countries); a major presence in Mumbai, India, and Suzhou, China; and a substantial centre in Prato, Italy. This global network enriches education and research, and nurtures deep, enduring relationships across the world.

 

The University of Melbourne is a global leader in higher education. Across their campuses we convene brilliant minds from different disciplines and sectors to come together to address important questions and tackle grand challenges. In a disrupted world, that capacity has never been more important.

In the spirit of discovery, the University convenes experts from around the world to tackle complex problems in innovative ways with investigator-led, interdisciplinary collaboration central to our purpose as a comprehensive research organisation. The University works with industry partners and specialist research institutes to address the major challenges that exist in the world.

The University is embedded within world-leading clusters of expertise, including the Melbourne Biomedical Precinct, Melbourne Innovation District through Melbourne Connect, Southbank Arts Precinct, and the heavy engineering and design precinct to be located at Fishermans Bend. The University plays a leading role within these precincts to amplify the benefits of research.

 

Victoria is home to one of the world’s leading health technology hubs, including the medical technology, biotechnology and pharmaceutical industry sectors, supported by its globally recognised medical research institutes, teaching hospitals and universities. It is a preferred location for many international organisations including CSL, Moderna, BioNTech, Illumina, Telix Pharmaceuticals and Pfizer.

Victoria is a key generator of new innovative therapeutics built on world class research, a vibrant commercial biotech sector, significant R&D infrastructure, services and manufacturing expertise. Victoria is currently home to 81 ASX-listed health technology companies, with a combined market capitalisation of over $172 billion. More than 22 pharmaceutical manufacturers are located in Victoria as well as a growing range of specialised service providers, all working to produce a variety of products for international markets using advanced manufacturing technologies.

In 2023, Victoria’s pharmaceutical products exports accounted for more than $3.02 billion, making it one of Victoria’s highest-value manufactured export categories. The Victorian Government has provided consistent, long-term support for the sector, providing significant funding for capabilities and supporting infrastructure.